Hazarapetyan LG, Zelveian PH and Grigoryan SV*

Yerevan State Medical University, National Medical Center 'Yerevan', 2 Koryun Street, Yerevan, Armenia

*Corresponding Author: Grigoryan SV, Yerevan State Medical University, National Medical Center 'Yerevan', 2 Koryun Street, Yerevan, Armenia.

Received: June 25, 2025; Published: July 16, 2025

Abstract

Atrial fibrillation (AF) is the most common arrhythmia with heterogeneous clinical manifestations and severe complications such as heart failure and stroke. Atrial fibrillation has a multi-factorial nature and complex pathogenesis. The process of atrial remodeling is the basis of the occurrence and recurrence of AF, which affects the electrical, contractile, structural function and also impact on autonomic nervous system dysfunction, which leads to their morphological changes in atrium [1].

References

1. Murakata Y., et al. “Electrical, structural, and autonomic atrial remodeling underlies atrial fibrillation in inflammatory atrial cardiomyopathy”. Frontiers in Cardiovascular Medicine 9 (2023): 1075358.
2. Nattel S and Harada M. “Atrial remodeling and atrial fibrillation: recent advances and translational perspectives”. Journal of the American College of Cardiology 63 (2014): 2335-2345.
3. Sagnard A., et al. “New perspective in atrial fibrillation”. Journal of Clinical Medicine 9 (2020): 3713.
4. Heijman J., et al. “Dynamics of atrial fibrillation mechanisms and comorbidities”. Annual Review of Physiology 83 (2021): 83-106.
5. Nattel S. “Atrial Fibrosis, Endocardial Damage, and Thrombosis in Atrial Fibrillation: Association with Underlying Conditions or Causal?” JACC Clinical Electrophysiology 9 (2023): 1169-1171.
6. Li Z., et al. “Atrial Cardiomyopathy Markers and New-Onset Atrial Fibrillation Risk in Patients with Acute Myocardial Infarction”. European Journal of Internal Medicine 102 (2022): 72-79.
7. Schotten U., et al. “Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal”. Physiology Review 91 (2011): 265-232.
8. Korantzopoulos P., et al. “Inflammation and Atrial Fibrillation: A Comprehensive Review”. Journal of Arrhythmia 34 (2018): 394-401.
9. Heijman J., et al. “Dynamics of Atrial Fibrillation Mechanisms and Comorbidities”. Annual Review of Physiology 83 (2021): 83-106.
10. Verheule S and Schotten U. “Electrophysiological Consequences of Cardiac Fibrosis”. Cells 10 (2022): 3220.
11. Maesen B., et al. “Endomysial Fibrosis, Rather than Overall Connective Tissue Content, Is the Main Determinant of Conduction Disturbances in Human Atrial Fibrillation”. EP Europace 24 (2022): 1015-1024.
12. Li CY., et al. “Atrial fibrosis underlying atrial fibrillation (Review)”. International Journal of Molecular Medicine 3 (2021): 9.
13. Chelu MG., et al. “Atrial Fibrosis by Late Gadolinium Enhancement Magnetic Resonance Imaging and Catheter Ablation of Atrial Fibrillation: 5‐Year Follow‐Up Data”. Journal of American Heart Association 7 (2018): e006313.
14. Eckstein J., et al. “Impact of left atrial appendage fibrosis onatrial fibrillation in patients following coronary bypass surgery”. Clinical Cardiology10 (2022): 1029-1035.
15. Ma J., et al. “Left atrial fibrosis in atrial fibrillation: Mechanisms, clinical evaluation and management”. Journal of Cellular and Molecular Medicine6 (2021): 2764-2775.
16. Frangogiannis NG. “Cardiac fibrosis”. Cardiovascular Research6 (2021): 1450-1488.
17. Speca S., et al. “Cellular and molecular mechanisms of intestinal fibrosis”. World Journal of Gastroenterology 28 (2012): 3635-3661.
18. Al Qudah M., et al. “Targeting the renin-angiotensin-aldosterone system in fibrosis”. Matrix Biology (2021): 91-92: 92-108.
19. Kim KK., et al. “TGF-β1 Signaling and Tissue Fibrosis”. Cold Spring Harbor Perspectives in Biology4 (2018): a022293.
20. Li C., et al. “Mechanism of action of non-coding RNAs and traditional Chinese medicine in myocardial fibrosis: Focus on the TGF-β/Smad signaling pathway”. Frontiers in Pharmacology 14 (2023): 1092148.
21. Tian-lun Li., et al. “Omentin-1 attenuates atrial fibrillation via Src/PI3K/Akt signaling-mediated anti-fibrotic effects in cardiac fibroblasts”. European Journal of Pharmacology 996 (2025): 177588.
22. Kapelios CJ., et al. “Effect of Mineralocorticoid Receptor Antagonists on Cardiac Function in Patients with Heart Failure and Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”. Heart Failure Review 24 (2019): 367-377.
23. Karakasis P., et al. “Effects of Mineralocorticoid Receptor Antagonists on New-Onset or Recurrent Atrial Fibrillation: A Bayesian and Frequentist Network Meta-Analysis of Randomized Trials”. Current Problems in Cardiology 49 (2024): 102742.
24. Yang L., et al. “Effects and Mechanisms of SGLT2 Inhibitors on the NLRP3 Inflammasome, with a Focus on Atherosclerosis”. Frontiers in Endocrinology 13 (2022): 99293.
25. Søndergaard E., et al. “SGLT2 Inhibition Reduces Myocardial Oxygen Consumption”. Metabolism Open 15 (2022): 100207.
26. Dyck JRB., et al. “Cardiac Mechanisms of the Beneficial Effects of SGLT2 Inhibitors in Heart Failure: Evidence for Potential off-Target Effects”. Journal of Molecular and Cellular Cardiology 167 (2022): 17-31.
27. Packer, M. SGLT2 Inhibitors: Role in Protective Reprogramming of Cardiac Nutrient Transport and Metabolism”. Nature Reviews Cardiology 20 (2023): 443-462.
28. Søndergaard E., et al. “SGLT2 Inhibition Reduces Myocardial Oxygen Consumption”. Metabolism Open 15 (2022): 100207.
29. Yadav P., et al. “Glucagon-like Peptide 1 and Fibroblast Growth Factor-21 in Non-Alcoholic Steatohepatitis: An Experimental to Clinical Perspective”. Pharmacology Research 184 (2022): 106426.
30. Alharbi SH. “Anti-Inflammatory Role of Glucagon-like Peptide 1 Receptor Agonists and Its Clinical Implications”. Therapeutic Advances in Endocrinology and Metabolism 15 (2024): 20420188231222370.
31. Mehdi SF., et al. “Glucagon-like Peptide-1: A Multi-Faceted Anti-Inflammatory Agent”. Frontiers in Immunology 14 (2023): 1148209.
32. Solomon SD., et al. “Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure”. Journal of the American College of Cardiology 84 (2024): 1587-1602.

Citation

Citation: Grigoryan SV., et al. “Fibrosis and Atrial Fibrillation: The Role of Antifibrotic Treatment in the Therapy of AF”.Acta Scientific Medical Sciences 9.8 (2025): 42-45.

Copyright

Copyright: © 2025 Grigoryan SV., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.